ABVC BioPharma reports Q2 EPS (9c) vs (68c) last year

Reports Q2 revenue $117.14k vs $6.109ak st year. Dr. Uttam Patil, ABVC Chief Executive Officer, commented, “We are thrilled with the substantial progress we have made in Q2 2024. Our financial performance and strategic licensing agreements have enhanced our cash reserves and strengthened our position in the biopharmaceutical industry. We remain focused on advancing our pipeline, expanding our partnerships, and driving sustainable growth for the benefit of our shareholders.”